Financial Performance - The company's operating revenue for 2023 was approximately ¥6.57 billion, representing a 2.16% increase compared to ¥6.43 billion in 2022[34]. - Net profit attributable to shareholders decreased by 41.00% to ¥426.82 million in 2023 from ¥723.42 million in 2022[34]. - The net profit after deducting non-recurring gains and losses was ¥387.77 million, down 42.34% from ¥672.56 million in the previous year[34]. - The net cash flow from operating activities fell by 38.15% to ¥950.23 million, compared to ¥1.54 billion in 2022[34]. - The company's total assets increased by 2.00% to ¥25.72 billion at the end of 2023, up from ¥25.22 billion at the end of 2022[34]. - Basic earnings per share decreased by 40.74% to ¥0.32 in 2023, down from ¥0.54 in 2022[39]. - The weighted average return on equity dropped to 2.49%, a decrease of 1.70 percentage points from 4.19% in the previous year[39]. - The company achieved operating revenue of 6.57 billion yuan, a year-on-year increase of 2.16%, with main business revenue accounting for 6.32 billion yuan, or 96.18% of total revenue[53]. - The company reported a total of ¥1.81 billion in revenue for the fourth quarter of 2023, with a net profit of ¥28.97 million[43]. Audit and Compliance - The company reported a standard unqualified audit opinion from Suya Jin Cheng Accounting Firm for the fiscal year 2023[8]. - The company's financial statements are signed and stamped by the chairman, financial director, and head of the finance department[18]. - The company has detailed potential risks in the "Management Discussion and Analysis" section of the report[15]. Company Information - The company’s stock is listed on the Shanghai Stock Exchange under the code 600682, with the abbreviation Nanjing Xinjiekou[27]. - The company’s registered office is located at No. 1 Zhongshan South Road, Nanjing, with a postal code of 210005[26]. - The company has no historical changes in its registered address[26]. - The company’s financial advisor is located at 4011 Shennan Avenue, Shenzhen, with the main responsible person being Zhang Tao[33]. - The company’s annual report is disclosed in Chinese Securities Journal, Shanghai Securities Journal, and Securities Times[26]. - The company’s contact information includes a phone number of 025-84761643 and an email address of irm@njxb.com[23]. Market and Business Development - The center store in Nanjing recorded a significant increase in foot traffic, reaching 25.1 million visitors for the year, a 53% year-on-year growth, marking a new high since foot traffic statistics began[53]. - The company successfully introduced 60 new brands in 2023, including 27 benchmark brands, with 2 being national first stores and 5 being Jiangsu first stores[53]. - Ankang Tong expanded its service network, successfully winning bids in 171 locations, and added 11 new cities to its service coverage during the reporting period[55]. - Ankang Tong's business revenue from long-term care insurance significantly increased, with operations now covering 24 cities nationwide[78]. - Natali sold over 3,200 new products during the reporting period, with a net increase of 2,500 core private pay users[59]. - The company received multiple honors, including "Outstanding Nursing Home" and "Excellent Service Point," reflecting its commitment to high service standards and customer satisfaction[57]. - The company introduced 21 new brands in its Wuhu store, conducting 20 major promotional events over 152 days[75]. - The center store's marketing strategy focused on leveraging brand advantages and enhancing customer engagement through various promotional activities[75]. - Ankang Tong was recognized as one of the "Top 100 Brands in China's Health and Elderly Care Industry" and received multiple awards for innovation and brand influence[57]. - Ankangtong participated in the formulation of a national standard for elderly care services, which was published in March 2023[79]. Healthcare Services - HeKang's nursing services provided over 10 million hours in 2023, representing a 7% year-on-year increase[82]. - HeKang expanded its market presence by entering eight new cities and first-time entry into Guizhou Province[79]. - Natali's nursing business maintained stable growth, with a focus on enhancing service capabilities to meet the needs of elderly care[82]. - Natali's international expansion targets the UK elderly care market, with plans for acquisition completion in 2024[82]. - Natali's collaboration with insurance companies has expanded to include specialized elderly care services and home modifications[83]. - The company launched a family health service package in partnership with Dahua Bank, covering comprehensive health needs[83]. Research and Development - The company has actively developed a new product pipeline, evaluating over 200 projects since 2022 to prepare for future growth[115]. - Research and development expenses amounted to 258.65 million RMB, an increase of 3.69% year-on-year[191]. - The company is advancing the implementation of a full cost accounting system to reduce operational costs and improve management efficiency[189]. - The company is focusing on digital hospital construction and increasing budget investments in information technology to enhance patient experience[189]. - The company is committed to continuous investment in research and development, focusing on stem cell technology advancements[200]. Human Resources - A total of 218 personnel were recruited throughout the year, including 19 senior title personnel and 42 master's degree or higher graduates, improving the talent structure[95]. - The company has established a comprehensive training system for cell therapy professionals, enhancing its competitive edge in the industry[186]. Industry Trends - The global cell and gene therapy (CGT) market size grew from $50 million in 2016 to $2.08 billion in 2020, with a compound annual growth rate (CAGR) of 153%[132]. - The Chinese CGT market is projected to reach ¥14.96 billion in 2022, with an expected growth rate exceeding 100% annually, reaching ¥178.85 billion by 2025[132]. - In 2023, 51 CGT companies completed financing exceeding ¥8 billion, indicating sustained investment interest despite market challenges[134]. - The total number of medical service visits in China from January to August 2023 reached 4.52 billion, with public hospitals accounting for 2.3 billion visits, a 2.6% year-on-year increase[135]. Community Engagement - The "Fire Seed Project 2.0" was launched to assist specific groups, with over 200 families aided and more than 10 million yuan raised[88]. - The hospital established a multi-disciplinary rescue system to enhance trauma rescue capabilities, supported by the Emergency Medicine and Orthopedics departments[94]. - The hospital's outpatient quality checks were conducted 12 times across 12 departments, ensuring high-quality service delivery[98]. - The hospital's new service offerings include immune cell storage and testing services, with a customer satisfaction rate of 99% from surveys conducted throughout the year[110].

证券代码：600682 证券简称：南京新百 公告编号：临 2024-010 南京新街口百货商店股份有限公司 2024年第一季度经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 南京新街口百货商店股份有限公司（以下简称公司）根据上海证券交易所《上市 公司自律监管指引第 3 号——行业信息披露》之《第四号——零售》的相关要求，现 将公司 2024 年第一季度主要经营数据（未经审计）公告如下： 一、2024 年第一季度主要经营数据如下： （一）主营业务分行业情况 | | | | 主营分行业 | 主营业务收入 | 主营业务成本 | 毛利率 | 营业收入比上年 | 营业成本比上年 | | --- | --- | --- | --- | --- | --- | | | | | （%） | 增减（%） | 增减（%） | | 商业 | 112,452,143.92 | 32,294,672.34 | 71.28 | -11.78 | -11.29 | | 宾馆餐饮业 | 7,110,023.09 | 940,967.88 | 8 ...

Financial Performance - The net profit attributable to shareholders for the first quarter of 2024 decreased by 27.96% compared to the same period last year, amounting to 166,209,752.08 CNY[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses also fell by 27.11% year-on-year[20] - Basic and diluted earnings per share decreased by 23.08% in the current reporting period[20] - The company's operating revenue for the first quarter of 2024 was CNY 1,580,283,271.46, representing a decrease of 0.96% compared to the same period last year[32] - Net profit attributable to shareholders of the parent company for Q1 2024 was RMB 129,782,239.87, down 28.06% from RMB 180,148,875.72 in Q1 2023[59] - Comprehensive income total for Q1 2024 was RMB 170,589,266.72, compared to RMB 94,650,336.08 in Q1 2023, indicating a significant increase[59] - The weighted average return on net assets was 0.75%, a decrease of 29.25 percentage points year-on-year[32] Assets and Liabilities - Total assets as of March 31, 2024, reached 25,993,671,127.42 CNY, an increase from 25,719,533,432.05 CNY at the end of 2023[12] - The total liabilities increased to 6,086,433,216.34 CNY from 5,966,368,169.54 CNY, reflecting a rise in short-term borrowings[12] - The total assets at the end of the reporting period amounted to CNY 25,993,671,127.42, an increase of 1.07% from the end of the previous year[32] - The equity attributable to shareholders of the listed company was CNY 17,452,388,682.10, which is a 0.78% increase compared to the previous year[32] - The total liabilities amounted to CNY 7,119,849,636.54, an increase from CNY 7,017,213,664.98 in the previous year[27] Cash Flow - The cash flow from operating activities decreased by 67.10% in the current reporting period, primarily due to a decline in sales collections[20] - The net cash flow from operating activities was CNY 74,516,956.63, reflecting a significant decline of 67.10% year-on-year[32] - Cash flow from operating activities for Q1 2024 was RMB 74,516,956.63, a decrease of 67.05% from RMB 226,467,680.60 in Q1 2023[62] - The net cash flow from investing activities was -281,492,719.20, compared to -191,781,349.33 in the previous period, indicating a decline of approximately 46.8%[63] - The total cash inflow from financing activities was 148,465,000.00, an increase from 137,210,000.00, reflecting a growth of about 24.0%[63] - The net cash flow from financing activities was -10,406,142.12, an improvement from -38,979,528.13, showing a reduction in cash outflow by approximately 73.3%[63] - The cash and cash equivalents at the end of the period decreased to 4,725,590,795.54 from 4,840,736,225.16, representing a decline of about 2.4%[63] - The total cash outflow from investing activities was 537,255,615.19, compared to 581,531,325.25 in the previous period, indicating a decrease of approximately 7.6%[63] - The cash outflow for repaying debts was 129,708,083.33, down from 150,734,078.37, reflecting a decrease of about 13.9%[63] - The company reported a net increase in cash and cash equivalents of -216,188,879.09, compared to -31,720,739.46 in the previous period, indicating a significant decline[63] Research and Development - Research and development expenses increased to 60,280,538.57 CNY from 57,587,714.27 CNY, indicating a focus on innovation[14] Other Financial Metrics - The cash inflow from minority shareholders' investments was not specified, but the overall financing activities showed a positive trend in cash inflow[63] - The total non-operating income and expenses amounted to -242,775.90, with an income tax impact of 2,321,758.21 and a minority interest impact of 2,803,409.59[65] - The impact of exchange rate changes on cash and cash equivalents was positive at 1,193,025.60, contrasting with a negative impact of -27,427,542.60 in the previous period[63] - Deferred tax assets amounted to RMB 338,091,127.95 as of the end of Q1 2024, slightly up from RMB 337,834,969.64 in Q1 2023[53] - The total cash outflow for purchasing fixed assets and intangible assets in Q1 2024 was RMB 48,655,615.19, compared to RMB 99,416,025.25 in Q1 2023[62] - The company reported a net loss of RMB 166,209,752.08 from discontinued operations in Q1 2024[59] - The total assets as of the end of Q1 2024 included oil and gas asset development expenditures of RMB 244,884,604.31[53]

证券代码：600682 证券简称：南京新百 公告编号：临 2024-003 南京新街口百货商店股份有限公司 关于股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司股东银丰生物工程集团有限公司（以下简称银丰生物）持有南京新 街口百货商店股份有限公司（以下简称公司）股份数量为 96,722,192 股，占公 司总股本的 7.19%。本次股份质押后，银丰生物累计质押数量为 96,684,164 股 （含本次），占其持有公司股份数的 99.96%，占公司总股本的 7.18%，剩余未质 押股份数量为 38,028 股。 公司于 2024 年 1 月 26 日收到股东银丰生物关于其所持公司股份质押登记的 说明，现将有关情况公告如下： 一、本次股份质押基本情况 2、银丰生物质押股份不存在被用作重大资产重组、业绩补偿等事项的担保或 其他保障用途。 3、股东累计质押股份情况 截止公告披露日，银丰生物及其一致行动人累计质押股份情况如下： 证券代码：600682 证券简称：南京新百 公告编号：临 2024- ...

证券代码：600682 证券简称：南京新百 公告编号：临 2024-002 南京新街口百货商店股份有限公司 第十届董事会第八次会议决议公告 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京新街口百货商店股份有限公司（以下简称公司）第十届董事会第八次会 议（以下简称会议）于 2024 年 1 月 8 日以通讯表决的方式召开。本次会议应参 会董事 11 人，实际参会董事 11 人。本次会议的通知、召开以及参与表决董事人 数均符合有关法律、法规、规则及《公司章程》的规定。会议审议并通过了《关 于补选第十届董事会副董事长的议案》。 公司董事会于近日收到公司副董事长张轩先生递交的辞职报告，张轩先生因 公司工作调整原因，向公司辞去副董事长职务，辞职后张轩先生将不再担任公司 副董事长职务。为完善公司治理结构，根据《公司章程》等规定，公司董事会拟 选举袁千惠女士为公司副董事长，任期与本届董事会任期相同。简历详见附件。 表决结果：11 票同意，0 票反对，0 票弃权。 特此公告。 南京新街口百货商店股份有限公司 董事会 2024 年 1 ...

江苏泰和律师事务所 关于南京新街口百货商店股份有限公司 2024 年第一次临时股东大会的 法律意见书 泰和律师事务所 法律意见书 法律意见书 致：南京新街口百货商店股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》、中国证券监督 管理委员会《上市公司股东大会规则》、《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》等法律、法规、规范性文件和《南京新街口百货商店股 份有限公司章程》（以下简称"《公司章程》"）的有关规定，江苏泰和律师事 务所（以下简称"本所"）接受南京新街口百货商店股份有限公司（以下简称"公 司"）的委托，指派律师（以下简称"本所律师"）出席公司 2024 年第一次临 时股东大会（以下简称"本次股东大会"、"会议"），并出具本法律意见书。 为出具本法律意见书，本所律师依据《律师事务所从事证券法律业务管理办 法》和《律师事务所证券法律业务执业规则(试行)》等规定，严格履行了法定职 责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事项进行了 必要的核查和验证，并全程参加了本次股东大会。 本所保证本法律意见书所认定的事实真实、准确、完整，所发表的结论性意 见合法 ...

重要内容提示： 本次会议是否有否决议案：无 证券代码：600682 证券简称：600682 公告编号：2024-001 南京新街口百货商店股份有限公司 2024 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 远扬律师、黎达侨律师为本次股东大会见证律师。本次股东大会的召集、召开及 表决方式符合法律法规的规定。 (五) 公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 (一) 累积投票议案表决情况 1、 关于补选第十届董事会非独立董事的议案 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 29 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 818,488,136 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 60.8029 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，大会由副董事长张轩先生主持。本次大会 采取现场投票和 ...

南京新街口百货商店股份有限公司 二〇二四年第一次临时股东大会资料 2024 年 1 月 南京新街口百货商店股份有限公司 2024 年第一次临时股东大会资料 南京新街口百货商店股份有限公司 2024 年第一次临时股东大会议程 一、现场会议时间：2024 年 1 月 3 日 14 点 30 分； 二、现场会议地点：南京市雨花台区软件大道 119 号丰盛五季凯悦臻选酒店一层悟 1 厅 会议室； 三、召集人：公司董事会； 四、会议出席人员：2023 年 12 月 26 日下午收市后，在中国证券登记结算有限责任公 司上海分公司登记在册的本公司全体股东或其合法委托的代理人；公司董事、监事及高级 管理人员、公司聘请的律师； 五、表决方式：采取现场投票和网络投票相结合的方式； 六、会议议程； 七、主持人宣布现场会议开始； 八、宣读、审议如下议案； | 序号 | 议案名称 | 投票股东类型 | | --- | --- | --- | | | | A 股股东 | | 累积投票议案 | | | | 1.00 | 关于补选第十届董事会非独立董事的议案 | 应选董事（1）人 | | 1.01 | 选举袁千惠女士为第十届董事会董事 | ...

证券代码：600682 证券简称：南京新百 公告编号：2023-039 召开的日期时间：2024 年 1 月 3 日 14 点 30 分 召开地点：南京市雨花台区软件大道 119 号丰盛五季凯悦臻选酒店一层悟 1 厅会议室 股东大会召开日期：2024年1月3日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 南京新街口百货商店股份有限公司 关于召开 2024 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024 年第一次临时股东大会 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 1 月 3 日 至 2024 年 1 月 3 日 采用上海证券交易所网络投票系统，通过交易系 ...

证券代码： 600682 证券简称：南京新百 公告编号：临2023-037 南京新街口百货商店股份有限公司 第十届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京新街口百货商店股份有限公司(以下简称公司)第十届董事会第七次会 议(以下简称会议)于2023年12月15日以通讯表决的方式召开。会议通知于2023年 12月12日以电话或邮件的方式向全体董事发出，本次会议应参会董事10人，实际参 会董事10人。本次会议的通知、召开以及参与表决董事人数均符合有关法律、法规 、规则及《公司章程》的规定。会议审议并通过了如下议案： 公司董事会非独立董事张雷先生因公司工作调整原因，向公司辞去公司董事 职务。根据《公司法》、《上海证券交易所股票上市规则》及《公司章程》的相关 规定和董事会提名委员会的提名及资格审查，经公司第十届董事会第七次会议审议 ，同意提名袁千惠女士为公司第十届董事会非独立董事候选人。其任期自股东大会 通过之日起至本届董事会任期届满为止。简历详见附件。 本议案尚需提交至公司股东大会审议。 表决结果 ...